EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy

Nicholas T Funderburg iD, Allison Ross Eckard iD, Qian Wu, Abdus Sattar iD, Kate Ailstock, Morgan Cummings, Danielle Labbato, Grace A McComsey iD

Open Forum Infectious Diseases · 27.03.2025 · 12 (4)

DOI: 10.1093/ofid/ofaf152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 20.03.2025. Verfasst von Nicholas T Funderburg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Laboratory Sciences, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, Ohio, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiovascular and metabolic comorbidities are common in people with HIV (PWH) and are linked to chronic inflammation and immune activation. We assessed the effects of semaglutide on plasma markers of immune activation/inflammation that are known to be increased in PWH and are associated with morbidity and mortality in this population.

Methods

We conducted a single-site, randomized, double-blinded, placebo-controlled trial of virologically suppressed, nondiabetic PWH ≥18 years of age on stable antiretroviral therapy with body mass index ≥ 25 kg/m2, increased waist circumference/waist-to-hip ratio, and subjective increased abdominal girth after antiretroviral therapy initiation (clinicaltrials.gov: NCT04019197). Participants were randomized 1:1 to 32 weeks of semaglutide (8-week titration + 24 weeks of 1.0 mg weekly subcutaneous injection) or matching placebo. Signed-rank tests were used to determine changes over 32 weeks in soluble markers and cellular phenotypes of inflammation/immune activation within groups; semaglutide effects were assessed using linear or quantile regression analyses.

Results

A total of 108 participants were enrolled and evenly randomized to semaglutide versus placebo. Eight (15%) in each group withdrew prematurely. Thirty-two weeks of semaglutide treatment reduced baseline levels of C-reactive protein, interleukin-6, and soluble CD163 (all P < .02) and trended to reduce levels of sCD14 (P = .08). Circulating monocyte proportions and T-cell phenotypes were not altered by semaglutide.

Conclusions

In this randomized controlled trial of semaglutide in PWH, we report significant decreases in markers of inflammation that are associated with morbidity and mortality in this population. These results add to the growing literature demonstrating the anti-inflammatory effects of semaglutide. Further studies in PWH are warranted.

Schlagwörter

Stichwörter der Autor:innen

C-reactive proteinHIV-1inflammationinterleukin-6semaglutide

Autor:innen und Institutionen

  • Division of Medical Laboratory Sciences, School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, Ohio, USA.
  • Departments of Pediatrics and Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
  • Departments of Pediatrics and Medicine, University Hospitals of Cleveland, Cleveland, Ohio, USA.

ORCID-Profile: Nicholas T Funderburg, Allison Ross Eckard, Abdus Sattar, Grace A McComsey

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • Clinical and Translational Science Collaborative (CTSC) of Northern Ohio
  • National Center for Advancing Translational Sciences

Zitieren

APA

Funderburg, N. T., Ross Eckard, A., Wu, Q., Sattar, A., Ailstock, K., Cummings, M., Labbato, D., & McComsey, G. A. (2025). The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy. Open Forum Infectious Diseases, 12(4). https://doi.org/10.1093/ofid/ofaf152

Vancouver

Funderburg NT, Ross Eckard A, Wu Q, Sattar A, Ailstock K, Cummings M, et al. The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy. Open Forum Infectious Diseases. 2025;12(4). doi:10.1093/ofid/ofaf152

BibTeX
@article{Funderburg2025,
  author = {Funderburg, Nicholas T and Ross Eckard, Allison and Wu, Qian and Sattar, Abdus and Ailstock, Kate and Cummings, Morgan and Labbato, Danielle and McComsey, Grace A},
  title = {The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {12},
  number = {4},
  doi = {10.1093/ofid/ofaf152}
}
Kostenlos starten →